Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absorption, Metabolism, and Excretion of [14C]-Simufilam in Healthy Men
NCT06195319Phase 1Completed
- Sponsor
- Cassava Sciences
- Start
- Feb 2024
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of simufilam in Alzheimer's disease (AD), sponsored by Cassava Sciences. Primary endpoints: Area Under the Curve at 10 days, Maximum Plasma Concentration at 10 days and 3 more. Started Feb 2024; status: completed.
02
Drugs
simufilam
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06195319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06195319.